Three insights:
1. The rebranding reflects the company’s work with fibroblasts, which includes cell therapy treatments for chronic diseases and the development of a potential cure for degenerative disc disease.
2. The company has 180 issued and pending patents in a variety of areas, including disc degeneration, multiple sclerosis and Parkinson’s.
3. FibroGenesis, completely funded by angel investors, will be wholly owned by SpinalCyte.
More articles on devices:
Bundled payments in spine: 12 key thoughts for 2020
Breaking down the 3 major robots in spine surgery
8 spine, neurosurgeon moves
